MASCT-I + camrelizumab + apatinib

MASCT-I + camrelizumab + apatinib is a **combination therapy regimen** consisting of: - **MASCT-I:** a personalized dendritic cell-CTL vaccine developed using the patient’s own tumor antigens presented to autologous T cells via dendritic cell pulsing, inducing a tumor-targeted immune response. - **Camrelizumab:** a humanized IgG4 monoclonal antibody targeting the programmed cell death protein 1 (**PD-1**), functioning as an **immune checkpoint inhibitor** by blocking the PD-1/PD-L1 pathway and thereby enhancing T-cell-mediated anti-tumor immunity[1][3][4][6][7][8]. - **Apatinib:** a **small molecule tyrosine kinase inhibitor** (TKI) that specifically inhibits vascular endothelial growth factor receptor 2 (**VEGFR2**), suppressing tumor angiogenesis and normalizing tumor vasculature to facilitate immune cell infiltration[1][3][4][6][7][8]. This combination aims to synergistically enhance anti-tumor efficacy by promoting both adaptive and innate immune responses while disrupting tumor blood supply. Primary indications under study include various advanced solid malignancies, notably hepatocellular carcinoma, adrenocortical carcinoma, recurrent/metastatic nasopharyngeal carcinoma, advanced cervical cancer, and others[1][3][4][6][7][8]. Specific clinical trial information for the tri-combination (including MASCT-I) is limited, but camrelizumab + apatinib (duo) is being actively pursued in multiple tumor types.